MacroGenics - MGNX Stock Forecast, Price & News

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

MacroGenics Trading Up 3.7 %

Shares of MacroGenics stock traded up $0.19 during trading on Friday, reaching $5.28. The company's stock had a trading volume of 20,763 shares, compared to its average volume of 1,105,559. The stock has a 50-day moving average price of $3.42 and a two-hundred day moving average price of $6.54. MacroGenics has a one year low of $2.13 and a one year high of $28.09. The stock has a market capitalization of $324.51 million, a P/E ratio of -1.43 and a beta of 2.08.

Wall Street Analyst Weigh In

MGNX has been the topic of a number of research analyst reports. Guggenheim downgraded shares of MacroGenics from a "buy" rating to a "neutral" rating in a research note on Wednesday, May 4th. BTIG Research set a $6.00 target price on shares of MacroGenics in a research report on Tuesday, July 19th. Sumitomo Mitsui Financial Group lowered shares of MacroGenics from an "outperform" rating to a "neutral" rating and set a $5.00 price objective for the company. in a research report on Monday, July 18th. HC Wainwright decreased their target price on shares of MacroGenics from $41.00 to $35.00 in a report on Wednesday, May 4th. Finally, JMP Securities reduced their price target on shares of MacroGenics from $24.00 to $20.00 and set a "market outperform" rating for the company in a research report on Tuesday, July 12th. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $15.67.

Insider Transactions at MacroGenics

In other news, CFO James Karrels purchased 40,000 shares of MacroGenics stock in a transaction on Wednesday, June 15th. The stock was purchased at an average price of $2.47 per share, with a total value of $98,800.00. Following the transaction, the chief financial officer now directly owns 191,776 shares in the company, valued at approximately $473,686.72. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 7.90% of the company's stock.